In 2016, nearly 110,000 women in the United States alone underwent breast reconstruction by members of the American Society of Plastic Surgeons (ASPS), of which roughly 90,000 elected for tissue expander-implant or implant only techniques. These rates continue to rise as breast reconstruction establishes itself as one of the main pillars in the treatment of breast cancer patients. This is in part because the benefits of reconstruction are manifold, restoring a patient’s form and sense of self in addition to providing psychosocial wellbeing and aesthetic benefits.

Nonetheless, mastectomy interrupts the axial blood supply to the skin overlying the breast, creating a relatively hypovascular milieu and skin flaps prone to wound breakdown and tissue necrosis in 3 to 33% of cases. Particularly in prosthetic breast reconstruction, the viability of these mastectomy skin flaps is of utmost importance to prevent implant exposure leading to explantation, delays in adjuvant chemoradiation, and possible reconstructive failure. To the plastic surgeon, mastectomy flap necrosis should represent a “never event;” however, we lack the tools to make this the reality.

As such, predicting the risk for mastectomy flap necrosis intraoperatively has been the subject of much research lately. Techniques using fluorescein or indocyanine green angiography have yielded mixed results. Translating intraoperative measurements of ischemia, whether quantitative or visual, to full-thickness necrosis has proven challenging, particularly in the context of the hemodynamic changes that occur during and after surgery. Downsides including cost, device bulkiness, risk of allergic reaction, and challenges interpreting output have prevented their widespread incorporation into clinical practice. The plan of this manuscript is to review the evidence on mastectomy skin flap perfusion analysis, highlighting the benefits, and downsides of the current technologies and identifying exciting areas of future research and development.
The true risk of mastectomy skin flap necrosis following immediate prosthetic reconstruction is difficult to pinpoint and a broad range of estimates have been reported within the literature.5–9 This is in part due to the variations in the definition of flap necrosis across studies. Full-thickness necrosis is rare and occurs on the order of 3 to 9% across studies; partial thickness necrosis rates have been reported as high as 30 to 40%.6,7,22–25 Scales, including the SKIN score more precisely delineate the depth of an area of tissue injury,26 but no one system has been broadly adopted by the research community.

Moreover, estimates of average, population-level risk are not always relevant to the individual patient.27,28 and in the case of flap necrosis, factors such as smoking status, mastectomy technique, flap thickness, and flap length play a considerable role in determining risk. Because of this heterogeneity, meta-analysis of flap necrosis rates proved to be challenging and of dubious value; to our knowledge, no such attempt has been published within the literature.

Clinical Examination

Perhaps the oldest and most widely used method to assess mastectomy skin flaps, several studies have demonstrated the unpredictability of clinical exam in accurately and precisely predicting flap necrosis. Surgeons can evaluate for flap length or thinness, uneven flaps, ecchymosis, capillary refill, color, temperature, or bleeding from skin edges, and trim back to healthy tissue as needed. However, when decisions are based on clinical exam alone, flap necrosis rates remain elevated between 4% to 40%.6,7,22–24 Even with a "low-threshold" to excise questionable skin, necrosis rates can be as high as 27%,14 with multiple large series reporting specificities for clinical exam in the 10 to 30% range.29–31 Not only has clinical exam been demonstrated to be inferior to more objective methods of perfusion assessment,15,29,32 but the degree/thickness of the associated necrosis tends to be more severe.31 In general, a concerning exam represents a “tip of the iceberg,” as only the most foregone of tissues will declare themselves on the table to the naked eye.

Several clinical variables, beyond the physical exam and patient comorbidities, have also been correlated with the incidence of flap necrosis. The volume and weight of the tissue expander applies pressure on the already tenuous flaps and can exacerbate tissue ischemia and necrosis. The weight of the mastectomy specimen is also a useful variable,
both in and of itself, but also as a correlate for flap length and expander volume/weight.\textsuperscript{34} It is also important to note that clinical flap assessment is particularly challenging in patients with darker skin as the ability to perceive color changes and capillary refill may be obscured by high melanin concentrations.\textsuperscript{35}

**Angiography**

**Fluorescein**

The use of fluorescein to evaluate mastectomy skin flap viability was first described in the late 1970s by Singer and colleagues.\textsuperscript{36} Their cohort demonstrated its merit in identifying healthy and well perfused flaps but acknowledged its limitation in precisely delineating the extent and thickness of necrosis in concerning ones. After the completion of mastectomy, a weight based (10–15 mg/kg)\textsuperscript{33,36} or fixed (approximately 500–1,000 mg)\textsuperscript{14,37} dose of fluorescein is administered intravenously and allowed 15 minutes to circulate throughout the flaps. A Wood’s lamp or a more modern “black light,” that emits 320 to 500 nm wavelength ultraviolet light, is then turned on and used to visibly assess the diffusion of the fluorescein throughout the tissues. Well perfused flaps will glow yellow, whereas poorly perfused regions appear blue, and intermediate areas as yellow with blue mottling. The dye is generally well tolerated and excreted within the urine in 12 to 18 hours; side effects are rare and most commonly include nausea and vomiting. Allergic reactions, typically comprised of urticaria and fever, have been reported in 0.6% of patients, and more severe adverse including vasovagal reactions or cardiopulmonary events are rare.\textsuperscript{37–39}

Several studies\textsuperscript{14,23,37} have built upon Singer’s original data demonstrating a very high positive predictive value for areas that fluoresce of well over 90%, but blue areas continue to underpredict flap survival with false negative rates as high as 75%.\textsuperscript{37} Therefore, while using fluorescein to guide skin resection certainly decreases flap necrosis (to as low as 3% in one study\textsuperscript{14}), as much as 80% of the resected area may actually go on to survive.\textsuperscript{23} Surgeons are again left with clinical judgement to discern between true and false negatives, often weighing the size and location of hypoperfusion, flap thickness, and signs of retraction or electrocautery injury, as well as the patient’s radiation history.\textsuperscript{37} The presence of vasoconstrictive agents, such as epinephrine from a tumescent mastectomy,\textsuperscript{40} may also limit dye uptake and study results. The primary limitation of this technique, and many of others described in the literature, is that they afford only a single snapshot of perfusion even though blood flow is constantly changing in the perioperative period due to a patient’s hemodynamic state, cholinergic tone, and the insult of a surgical procedure. Porcine data have demonstrated an increase in flap fluorescence area of roughly 20% within 24 hours after flap elevation.\textsuperscript{41}

No studies to date have evaluated cost, patient reported outcomes, or aesthetic results in patients managed using intraoperative fluorescein angiography. Future prospective randomized data will be necessary to compare algorithms using fluorescein and clinical judgement against other techniques for flap evaluation.

**Indocyanine Green**

Indocyanine green (ICG) is an intravenously administered, biliary-excreted dye that circulates throughout tissues and emits infrared light upon excitation. Compared with fluorescein, the dye has a faster uptake into the tissues requiring only about 2 minutes before evaluation. Molecularly, ICG is larger than fluorescein (775 vs. 375 kD) and more likely to bind to plasma proteins, making it more likely to stay within the intravascular compartment and resulting in a faster washout (2.5 minutes half-life vs. 23 minutes).\textsuperscript{42,43} These properties not only decrease operative/evaluation time but also result in a superior side effect profile\textsuperscript{44,45} and allow for multiple injections and image captures during the same procedure. Although rare, allergic responses, including anaphylaxis, have been reported following ICG administration.\textsuperscript{46} A typical dose in adults is 25 mg of ICG, with a recommended maximum dose of 2 mg/kg.\textsuperscript{47} Other cited benefits of ICG angiography compared with fluorescein include a more gentle learning curve that is not dependent on the operator’s handling of a Wood’s lamp as well as the potential for providing a quantified output (\textsuperscript{48}Table 1\textsuperscript{48}).

Several commercially available devices exist to evaluate ICG derived fluorescence in human tissues, including: the SPY Elite System (Novadaq, San Jose, CA; \textsuperscript{49}Fig. 2\textsuperscript{49}), FLARE (Curadel LLC Marlborough, MA), PDENeo (Hamamatsu Photonics Hamamatsu City, Shizuoka, Japan), and Fluobeam 800 (Fluoptics, Cambridge, MA).\textsuperscript{48} These devices include a sensor and a source that emits infrared light in the 760 to 785 nm wavelength range that excites the ICG molecule and triggers fluorescence in the 820 to 840 nm range.\textsuperscript{49} The SPY and FLARE systems further provide software that is able to covert fluorescence into a quantitative measurement. Although there are clinical or preclinical data for each of these systems in mastectomy flap perfusion analysis; the SPY system is by far the most extensively reported but also the most expensive with a device cost of $250,000 and per use cost of $650.\textsuperscript{48}

First described in humans in 1999,\textsuperscript{50} this technology was first applied to mastectomy flap evaluation in the early 2000s with De Lorenzi et al’s proof of concept demonstrating a difference in perfusion patterns between native nipples and those elevated with the mastectomy skin flap.\textsuperscript{51} Newman et al retrospectively reviewed ICG fluorescence data for 20 patients undergoing immediate tissue expander based breast reconstruction, including nine with flap necrosis, and in hindsight demonstrated a 95% correlation between intraoperative imaging and complications with a 100% sensitivity and 91% specificity.\textsuperscript{52} As surgeons began incorporating this technology into their intraoperative decision making, analyses of pre- and post-ICG implementation cohorts demonstrated a decrease in not only mastectomy skin flap necrosis but also unplanned reoperation rates by more than 50%.\textsuperscript{15,53} Prospective comparisons to clinical exam have similarly demonstrated improved outcomes with intraoperative laser assisted ICG angiography.\textsuperscript{14,23}

Not unlike fluorescein, early adopters of ICG faced the dilemma of overly conservative and aggressive resections threatening potentially viable tissues. Where ICG-based systems differed, however, was in their ability to quantify...
The SPY system uses its proprietary software, the SPY-Q (Novadaq, San Jose, CA), to calculate and report both absolute perfusion as an integer or relative perfusion as a percentage of a selected reference area within the field. These analyses can be done either in real time intraoperatively or post hoc. Mattison et al. used different thresholds to demonstrate that a higher cut-off value does not necessarily improve sensitivity and may even come at an increased cost in specificity, positive predictive value, and the unnecessary resection of as much as 10 cm² or more of skin. As they search for an accurate cut-off, some authors have advocated for the use of relative fluorescence in assessing perfusion, but these measurements are more prone to interuser variability than absolute cut-offs. Interestingly, these measurements appear to be confounded by smoking status, use of epinephrine (tumescent mastectomy), and even skin

<table>
<thead>
<tr>
<th>Pros</th>
<th>Indocyanine green angiography</th>
<th>Fluorescein dye angiography</th>
<th>Near-infrared spectroscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Quantitative analysis</td>
<td>• User dependent results</td>
<td>• Handheld device</td>
<td></td>
</tr>
<tr>
<td>• Large body of literature</td>
<td>• Intravenous dye-based</td>
<td>• Relatively cheap</td>
<td></td>
</tr>
<tr>
<td>• Faster dye washout than fluorescein</td>
<td>• Serial evaluation limited by dye</td>
<td>• Rapid serial measurements</td>
<td></td>
</tr>
<tr>
<td>• Visualize perfusion throughout entire flap</td>
<td>• Risk of allergic reaction</td>
<td>• Dye-free system</td>
<td></td>
</tr>
<tr>
<td>• More tolerable side effect profile than fluorescein</td>
<td>• Confounded by epinephrine</td>
<td>• Quantitative measurement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Requires specialized/bulky machinery</td>
<td>• outcome (oxygenation %)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Questionable cost-efficacy (approximately $650/use)</td>
<td>• Easily used outside of OR</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cons</th>
<th>Indocyanine green angiography</th>
<th>Fluorescein dye angiography</th>
<th>Near-infrared spectroscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Intravenous dye-based</td>
<td>• User dependent results</td>
<td>• Lack of clinical outcomes data</td>
<td></td>
</tr>
<tr>
<td>• Serial evaluation limited by dye</td>
<td>• Intravenous dye-based</td>
<td>• Highly localized measurements, unable to assess entire flap</td>
<td></td>
</tr>
<tr>
<td>• Risk of allergic reaction</td>
<td>• Serial evaluation limited by dye</td>
<td>• Potentially confounded by other chromophores (melanin)</td>
<td></td>
</tr>
<tr>
<td>• Confounded by epinephrine</td>
<td>• Risk of allergic reaction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Requires specialized/bulky machinery</td>
<td>• Confounded by epinephrine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Questionable cost-efficacy</td>
<td>• Requires Wood’s lamp</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(approximately $650/use)</td>
<td>• Relative paucity of outcomes data</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Predictive accuracy</th>
<th>Indocyanine green angiography</th>
<th>Fluorescein dye angiography</th>
<th>Near-infrared spectroscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>APU: 20, Sen: 100</td>
<td>APU: 20, Sen: 100</td>
<td>Losken et al. Sen: 75, Spec: 71</td>
<td></td>
</tr>
<tr>
<td>APU: 15, Sen: 100</td>
<td>APU: 15, Sen: 100</td>
<td>Phillips et al. Sen: 90, Spec: 30</td>
<td></td>
</tr>
<tr>
<td>APU: 10, Sen: 100</td>
<td>APU: 10, Sen: 100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APU: 7, Sen: 88</td>
<td>APU: 7, Sen: 88</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APU: 6, Sen: 75</td>
<td>APU: 6, Sen: 75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APU: 3, Sen: 38</td>
<td>APU: 3, Sen: 38</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: APU, absolute perfusion units; N/A, not available; OR, operating room; Sen, sensitivity; Spec, specificity.

*Indocyanine green data based on data using the SPY Elite system.

Fig. 2 Left, SPY Elite system for indocyanine green angiography. Right, ViOptix Intra.Ox handheld tissue oximeter.
pigmentation or a history of hypertension, but the relationships remain incompletely described. Sannic et al is the only group to date who described their algorithm for interpreting and applying these quantitative data in clinical practice; however, no prospective randomized data exist to support one protocol or perfusion cut-off over another. Overall, the use of ICG or fluorescein angiography does not appear to decrease mastectomy skin loss. If anything, their use may come at the increased cost of debriding healthy skin to ensure that all devitalized tissues are removed and to prevent the downstream cost and morbidity associated with flap necrosis. One study by Rinker compared the area of resection with ICG, fluorescein and clinical exam (–Table 2); however, these numbers are difficult to interpret due to the discrepancies in flap necrosis rates across the cohorts. Other studies comparing intraoperative predictions to clinical flap necrosis within the same patients demonstrate as much as 3 to 6 cm² of excess skin loss with ICG or 19 cm² with fluorescein that is corroborated by the modest specificities for these techniques (–Table 2). In the correct patient, this excess cost in tissue may be justified by the improvement in patient outcomes and preventing delays in adjuvant chemoradiation.

Overall, ICG angiography rates in immediate breast reconstruction have been on the rise in recent years. Despite the high upfront cost of an ICG detector as well as cost per use associated with the dye and other operative room equipment, Duggal et al also demonstrates a $614 cost saving per patient in reducing flap necrosis rates from 44 to 25% and reoperation rates from 14% to 6%. Other studies have not replicated these findings, however, particularly in the setting of a more modest reduction in adverse events. Kanuri et al performed a retrospective subgroup analysis identifying smoking, BMI > 30 kg/m², and mastectomy weight greater than 800 g as high-risk features that result in a net cost-savings. Further research will be necessary to better understand the cost and benefits associated with ICG angiography and to identify the subgroup of patients in whom this technology is most cost effective.

Spectroscopy

Light-based spectroscopy generally takes advantage of the hemoglobin molecule’s ability to absorb or reflect light at various wavelengths to provide an estimate of either perfusion or tissue oxygenation. These techniques benefit from being noninvasive in nature and have multiple applications in different tissues and clinical scenarios. Although limited in its application to mastectomy skin flaps, Laser Doppler flowmetry is one such hand-held technique that has more commonly been applied to breast free flaps. In this technique, moving blood cells within the dermal plexus cause a back scattering of photons that provides information on their speed and concentration as surrogates for perfusion. Laser speckle contrast imaging is a similar camera-based technique that is able to scan a large area of skin (typically 15 cm x 15 cm) and demonstrate the reflection of light by moving red blood cells in the dermal plexus, typically as a speckle pattern on the camera sensor giving the technique its name. Polarized light has also been described to visually assess circulation in tissues of interest. After polarized light in the hemoglobin spectrum (548 nm wavelength) is directed toward the target, a majority of it is either reflected off its surface in an orthogonal plane or scattered by hemoglobin molecules. Once the orthogonally reflected light is filtered by a polarizer, the remaining, transmitted light is that which has been scattered by hemoglobin; this is picked up by a charge coupled device camera to provide real-time images of the microcirculation at a similar contrast level to images obtained using fluorescent dyes. Although the latter two methods provide qualitative data on perfusion, several algorithms have been developed to provide estimates of red blood cell concentration or other values based on pixel values from the images.

Although several other similar techniques have been described, only one has been directly applied to mastectomy skin flaps to date and will be discussed in further detail.

Near-Infrared Oximetry

Near-infrared spectroscopy samples of hemoglobin in specific areas of tissue adjacent to a sensor, providing highly localized measurements of tissue oxygenation. It is based on the principle that oxygenated and deoxygenated hemoglobin are chromophores that interact with light differently. The device directs near-infrared light toward the tissue of interest, and its intensity, as it returns to the sensor, allows for the calculation of a relative percentage of the two molecules. The ViOptix T.Ox (ViOptix, Inc., Fremont, CA) has already been demonstrated to be specific and sensitive in the

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Comparisons of prospective results for skin resection area and specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluorescein</strong></td>
<td>6.2 cm² skin resection 3% flap necrosis</td>
</tr>
<tr>
<td><strong>ICG</strong></td>
<td>5.4 cm² skin resection 14% flap necrosis</td>
</tr>
<tr>
<td><strong>Clinical exam</strong></td>
<td>6.5 cm² skin resection 27% flap necrosis</td>
</tr>
</tbody>
</table>

Abbreviation: ICG, indocyanine green.
detection of postoperative vascular compromise in free tissue transfer, identifying impending complications earlier than alternatives modalities. Only one study has used the T.Ox intraoperatively on mastectomy skin flaps, demonstrating a significantly greater reduction in oxygenation in tissue that becomes necrotic compared with healthy tissues.

Several factors unrelated to tissue oxygen saturation can affect near-infrared oximetry measurements, including instrumentation of the device, ambient light, melanin concentration, and the presence of additional chromophores including methylene blue. Additionally, single sensor detectors are unable to effectively distinguish the effects of absorption versus tissue scattering on light intensity at the sensor. To this end, a more recently FDA (Food and Drug Administration) approved device, the Intra.Ox (ViOptix, Inc., Fremont, CA; Fig. 2), is designed with multiple sensors specifically to overcome these limitations for intraoperative use. The device is wireless, battery operated, and handheld allowing for multiple, rapid measurements throughout the procedure without the need for dye or bulky equipment. The device also provides information on the quality its reading to improve interuser reliability. Lohman et al identified 30% oxygenation predicted tissue necrosis in porcine fasciocutaneous flaps; however, this newest generation of technology has yet to be applied in human mastectomy skin flaps.

Future Directions
As these various technologies vie to define their role in the assessment of mastectomy skin flap perfusion, future studies will have to demonstrate each one’s potential value to patient care, specifically how they can each improve patient outcomes and curb medical costs. Within the issue of cost is entangled the question of the target population. For more expensive technologies with a high per use cost (e.g., ICG angiography) indiscriminate use may not prove feasible, and a more targeted, high-risk population will need to be defined. But does this apply to reusable, dye-free techniques like near-infrared spectroscopy? Is one technology clearly superior in all populations, or should the technique for flap assessment be selected on a case-by-case basis? Both theoretical and retrospective reviews of cost and benefit will allow us to better understand each technology’s strengths and limitations and to carve out its niche in clinical practice.

Studies evaluating these technologies in prepectoral breast reconstruction will also be useful given the recent resurgence of this technique. Many centers have begun to incorporate indocyanine green angiography in their flap assessment and pocket selection algorithm; however, the data are not yet available within the literature. In the context of questionable mastectomy flap viability, the additional layer of vascularized muscle may protect an expander from exposure and its downstream sequelae. In these select cases, pocket exchange at the time of expander implant exchange may prove to be a safer alternative.

The best time for flap assessment also remains an unanswered question. Perfusion measurements will undoubtedly vary immediately following mastectomy to after device insertion and even after skin closure with varying degrees of tension. The patient’s hemodynamic state is also likely to fluctuate throughout the perioperative period. Ideally, evaluation occurs intraoperatively when surgeons have the most control over changing aspects of the case to avoid a complication. Most studies to date have evaluated skin flaps prior to reconstruction, and it remains to be seen what changes should be expected after that. In general, additional stress on the flaps should be avoided after assessment to not confound the results.

With regards to outcomes, we currently lack prospective data to validate most of the regiments described within the literature. Different authors have put forth varying criteria for the resection of skin based on qualitative and/or quantitative assessment of its perfusion; which one appropriately identifies at risk tissue with the least amount of collateral damage? How do patient factors, including skin pigmentation or blood pressure weight into this? Also implicit to all of this is the issue of interuser variability for each technique. With several therapeutic options available beyond simply resecting at risk skin, including application of vasodilatory substances, such as nitroglycerine ointment, switching from single-stage to two-stage reconstruction, pocket selection, deflation of tissue expanders, or even delaying reconstruction altogether, we must better understand how to interpret these new objective data and navigate the intraoperative decision-making process.

Conclusion
Although objective assessment of tissue perfusion seems to have already delivered on its promise to prevent complications, in the era of value-based care, further research is necessary to do so reliably and efficiently on an even larger scale.

Conflict of Interest
None declared.

References
Mastectomy Flap Perfusion Assessment


42 Kuebler WM, Schell A, Habler O, et al. Noninvasive measurement of regional cerebral blood flow by near-infrared spectroscopy and